The U.S. House of Representatives approved the INVEST Act, a bipartisan package designed to free up capital for small innovative firms by removing regulatory barriers and expanding investor access. The Biotechnology Innovation Organization and industry leaders praised the vote as a way to bolster early‑stage funding for startups and improve the investment climate for biotechs. BIO’s Bradford Zakes said the bill would help bridge the funding gap from lab to clinic. If enacted in law, provisions in the package could alter fundraising dynamics, impact IPO readiness, and change how venture and retail investors engage with emerging life‑science companies. Companies, investors and policymakers will monitor Senate action and potential amendments.